ABSTRACT
Background The rst step in creating a biosimilar product portfolio is an overall understanding of the challenges, hurdles, difculties, and practicalities of a robust development plan and a strategy. Biosimilar product development strategies would not be the same as those of small-molecule generics that are approved under the Food and Drug Administration (FDA) 505 category, even if some biotechnology products were approved under the 505 category.
